Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.
Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement.
复制标题
DOI：
10.1097/tp.0000000000001055
复制
发表时间：
2016-02
期刊：
影响因子：
6.2
通讯作者：
Otonkoski T
中科院分区：
文献类型：
--
作者：
Bartlett ST;Markmann JF;Johnson P;Korsgren O;Hering BJ;Scharp D;Kay TW;Bromberg J;Odorico JS;Weir GC;Bridges N;Kandaswamy R;Stock P;Friend P;Gotoh M;Cooper DK;Park CG;OʼConnell P;Stabler C;Matsumoto S;Ludwig B;Choudhary P;Kovatchev B;Rickels MR;Sykes M;Wood K;Kraemer K;Hwa A;Stanley E;Ricordi C;Zimmerman M;Greenstein J;Montanya E;Otonkoski T
At the time the first pancreas transplant was performed by Kelly and Lillehei in 1966, insulin therapy for diabetes was generally available but administered in a form that is known today as “conventional therapy.” 1 In this era, as many as half of all juvenile onset diabetics did not reach the age of 55 years. Early mortality from accelerated cardiovascular disease, renal failure, and hypoglycemia-related events were commonplace. The early low success rate and mortality of pancreas transplantation by comparison were also suboptimal. As will be characterized in the succeeding 8 chapters, the outcome of “best medical therapy” with newer forms of insulin and insulin delivery systems along with dramatically improved outcomes of islet and pancreas transplantation and novel β-cell sources hold great promise for those afflicted.
